| Diabetes Mellitus, Non-Insulin-Dependent
Glyxambi vs Trijardy XR
Side-by-side clinical, coverage, and cost comparison for diabetes mellitus, non-insulin-dependent.Deep comparison between: Glyxambi vs Trijardy Xr with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTrijardy Xr has a higher rate of injection site reactions vs Glyxambi based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Trijardy Xr but not Glyxambi, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Glyxambi
Trijardy Xr
At A Glance
Oral
Daily
SGLT2 inhibitor / DPP-4 inhibitor
Oral
Daily
SGLT2i / DPP-4i / biguanide
Indications
- Diabetes Mellitus, Non-Insulin-Dependent
- Cardiovascular Diseases
- Diabetes Mellitus, Non-Insulin-Dependent
Dosing
Diabetes Mellitus, Non-Insulin-Dependent, Cardiovascular Diseases 10 mg empagliflozin/5 mg linagliptin once daily in the morning, with or without food; may increase to 25 mg empagliflozin/5 mg linagliptin once daily for additional glycemic control; not recommended with eGFR less than 30 mL/min/1.73 m2; withhold at least 3 days prior to surgery or procedures associated with prolonged fasting.
Diabetes Mellitus, Non-Insulin-Dependent Individualize starting dose based on current regimen; maximum 25 mg empagliflozin / 5 mg linagliptin / 2,000 mg metformin HCl once daily; take orally once daily with morning meal, swallow whole. Not recommended for initiation if eGFR <45 mL/min/1.73 m2; contraindicated if eGFR <30 mL/min/1.73 m2.
Contraindications
- Hypersensitivity to empagliflozin, linagliptin, or any excipient in GLYXAMBI (including anaphylaxis, angioedema, exfoliative skin conditions, urticaria, or bronchial hyperreactivity)
- Severe renal impairment (eGFR less than 30 mL/min/1.73 m2)
- Acute or chronic metabolic acidosis, including diabetic ketoacidosis
- Hypersensitivity to empagliflozin, linagliptin, metformin HCl, or any excipient (anaphylaxis, angioedema, exfoliative skin conditions, urticaria, or bronchial hyperreactivity have occurred)
Adverse Reactions
Most common (>=5%) Urinary tract infection, nasopharyngitis, upper respiratory tract infection
Serious Diabetic ketoacidosis, pancreatitis, volume depletion, urosepsis, pyelonephritis, necrotizing fasciitis of the perineum, genital mycotic infections, hypoglycemia with insulin or insulin secretagogues, lower limb amputation, hypersensitivity reactions, severe and disabling arthralgia, bullous pemphigoid, heart failure
Postmarketing Acute pancreatitis including fatal pancreatitis, constipation, mouth ulceration, stomatitis, anaphylaxis, angioedema, exfoliative skin conditions, necrotizing fasciitis of the perineum, urosepsis, pyelonephritis, ketoacidosis, rhabdomyolysis, acute kidney injury, bullous pemphigoid, rash, urticaria
Most common (>=5%) Upper respiratory tract infection, urinary tract infection, nasopharyngitis, diarrhea, constipation, headache, gastroenteritis
Serious Lactic acidosis, diabetic ketoacidosis, pancreatitis, volume depletion, genitourinary infections (urosepsis, pyelonephritis, Fournier's gangrene, genital mycotic infections), hypoglycemia with insulin or insulin secretagogues, lower limb amputation, hypersensitivity reactions, vitamin B12 deficiency, severe and disabling arthralgia, bullous pemphigoid, heart failure
Postmarketing Acute pancreatitis (including fatal), mouth ulceration, stomatitis, anaphylaxis, angioedema, exfoliative skin conditions, necrotizing fasciitis of the perineum, urosepsis, pyelonephritis, ketoacidosis, rhabdomyolysis, acute kidney injury, bullous pemphigoid, rash, urticaria, cholestatic and hepatocellular liver injury
Pharmacology
Empagliflozin is a SGLT2 inhibitor that reduces renal glucose reabsorption by inhibiting the predominant transporter responsible for filtered glucose reabsorption, thereby increasing urinary glucose excretion; linagliptin is a DPP-4 inhibitor that increases active incretin hormones (GLP-1 and GIP), stimulating glucose-dependent insulin secretion and reducing glucagon levels.
TRIJARDY XR combines three complementary mechanisms: empagliflozin (SGLT2 inhibitor) reduces renal glucose reabsorption and increases urinary glucose excretion; linagliptin (DPP-4 inhibitor) increases active incretin hormones (GLP-1, GIP) to stimulate glucose-dependent insulin release and reduce glucagon; and metformin HCl (biguanide) decreases hepatic glucose production, reduces intestinal glucose absorption, and improves peripheral insulin sensitivity.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Glyxambi
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (4/12) · Qty limit (11/12)
Trijardy Xr
- Covered on 5 commercial plans
- PA (4/12) · Step Therapy (5/12) · Qty limit (11/12)
UnitedHealthcare
Glyxambi
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (4/8) · Qty limit (6/8)
Trijardy Xr
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (6/8)
Humana
Glyxambi
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Trijardy Xr
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Glyxambi.
No savings programs available for Trijardy Xr.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
GlyxambiView full Glyxambi profile
Trijardy XrView full Trijardy Xr profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.